Moscow: Directors of the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba and the National Center for Medical Research in Endocrinology of Russia signed an agreement to expand scientific-medical ties on Tuesday. The signing ceremony was held at the Moscow Institute of Endocrinological Diseases, where its director, Natalia Mokrysheva, emphasized the importance of this collaboration in advancing joint work in the field of endocrinology.
According to Lao News Agency, Mokrysheva stated that the cooperation aims to introduce innovative treatment methods and promote scientific research, benefiting both patients and the broader medical community. She expressed confidence that the integration agreement with CIGB would enhance scientific cooperation, facilitate the exchange of experiences, and strengthen clinical training and business relations in medicine and healthcare.
CIGB Deputy General Director Jorge Vald©s shared his satisfaction with the consolidation of a long-standing friendship between the two centers through the agreement. He noted that the collaboration would enhance molecular genetic research for hereditary, genetic, and endocrine diseases, leveraging the capabilities of both institutions to benefit Russian and Cuban patients.
Vald©s highlighted that the agreement resulted from a decade of joint efforts, including the exchange of Cuban-origin therapies like Eberprot-P for diabetic foot ulcers. From 2017 to 2019, the National Medical Research Center of Endocrinology in Russia conducted clinical trials with Eberprot-P, demonstrating its efficacy in treating chronic lower limb wounds in diabetic patients.
Research conducted by the Russian institution confirmed that the drug, developed by ICSG specialists, significantly reduces wound healing time, hospital stays, and disability among patients. Based on these results, the treatment method was included in the clinical guidelines for diabetic foot ulcers in the Russian healthcare system.